Skip to main content

Quality of Harmonized Drug Substance Dossier for a Marketing Authorization

BayBiotech.NET

Through the ICH process (ICH M4Q), considerable harmonization has been achieved among the three regions (Japan, EU and US) in the technical requirements for the registration of pharmaceuticals for human use. To avoid the need to generate and compile different registration dossiers, the ICH: M4 guideline describes a format for the Common Technical Document that will be acceptable in all three regions.

In a nutshell, CTD is an internationally agreed upon format for the preparation of a presentation for applications to be submitted to the regulatory authorities. However, the CTD does not address the content of submissions. There are many regional requirements, as well as applicants’ preferences, that could affect the contents of dossiers submitted in each region.

According to the ICH guidelines, a document is defined for a paper submission as a set of pages, numbered sequentially and divided from other documents by a tab and a document can be equated to a file for an electronic submission. In an electronic submission, a new file starts at the same point at which in a paper submission, a tab divides the documents.
In deciding whether one or more documents or files are appropriate, it should be considered that once a particular approach has been adopted, the same approach should be used throughout the life of the dossier since it is the intention that replacement documents/files be provided when information is changed.

It is recommended that all the text and tables should be prepared using margins that allow the document to be printed on A4 paper (EU and Japan) and 8.5x11” paper (USA). Times New Roman, 12-point font is recommended for narrative text.

For more details follow the link: ICH M4Q Guideline Common Technical Document for the Registration of Pharmaceuticals for Human use, Quality

Comments

Popular posts from this blog

ISO Management Standards for Medical Devices

Two main ISO standards that have a direct application to Medical Device Industry are ISO 9001 and ISO 13485. While ISO 9001 is for evolving a Quality Management System for an organization, ISO 13485 has a direct application to Medical Device Industry. Although, ISO standards for a company are not a legal requirement, but provide a validation and ease of global marketing of the product.

A Facility Inspection Checklist

BayBiotech.NET Whether you are a Quality Assurance/ Compliance personnel planning to make a visit for a facility inspection, this checklist will help you prepare an inspection report based on the information that might be required to collect about the facility during the inspection. This checklist may help you evolve different forms for the inspection in order to accumulate complete information about the facility: 1.General information (a) name of establishment inspected (b) date of inspection (c) name(s) of the inspector(s) (d) date of last inspection. 2.Type of inspection Comprehensive, concise, follow-up, special, investigative, announced, and unannounced. 3.Licensing (a) licensing of premises (b) person with supervisory role in establishments (c) adherence to licensing provisions. 4. Activities undertaken on premises manufacturing, wholesale, importation, export, retail, hospital, pharmacy, clinic, nursing and maternity homes. 5. Adequacy and suitability of pre...

Current Status of Decentralized Clinical Trials

D2E Catalyst Past pandemic, concept of decentralized clinical trials (DCT) has drawn attention but yet not replaced traditional site-based trials. Currently, they have become a durable part of mainstream clinical operations, mostly in hybrid form. Regulators now clearly recognize decentralized elements such as telehealth visits, home-health visits, local labs, and remote data collection, and the FDA has formal guidance in place for how to run trials using those methods.   As of its current status, concept of DCT has won, but full decentralization has not. Sponsors are using decentralized components where they reduce patient burden or improve recruitment and retention, while keeping site-based procedures for activities that are harder to decentralize, such as complex exams, investigational product handling, or high-risk monitoring.  The evolving field is still constrained by several unresolved problems and recurring issues such as data quality and validation, operational c...